Celsion releases upbeat data for liver cancer drug; Curetis raises $16 million in Series B;

@FierceBiotech: E&Y: Biotech budget hawks rule the roost in year of mixed performance. Report | Follow @FierceBiotech

@RyanMFierce: RBC analyst Michael Ye says BMS' PhII data for all-oral reg isn't much of a threat to Gilead. So, again, Gilead is still the frontrunner. | Follow @RyanMFierce

> Convergence Pharmaceuticals has started a Phase II proof of concept study with its small molecule CNV2197944 for pain associated with post-herpetic neuralgia. Release

> Molecular diagnostics company Curetis AG closed a Series B financing round totaling €12.5 million ($16.24 million). Release

> Celsion ($CLSN) has released upbeat data from its HEAT study that its drug ThermoDox may be viable as a liver cancer drug. Release

> Isis Pharmaceuticals ($ISIS) has begun a Phase II study of its drug ISIS-SMNRx in infants with spinal muscular atrophy. Release

Medical Device News

@FierceMedDev: CareFusion endures another Class I pump recall. News | Follow @FierceMedDev

@MarkHFierce: Just attended our FierceBiotech breakfast and covered an R&D panel. Great ideas, but will they boost success rates? | Follow @MarkHFierce

 @DamianFierce: Roche Diagnostics is axing 170 jobs as its dissolves Applied Science biz. News | Follow @DamianFierce

> Cervel Neurotech snags $14.1M for anti-depression device. More

> Patent suit loss tanks Illumina's strong sales quarter. Story

> Report: Electrophysiology device sales grow fastest in Asia. Item

Pharma News

@FiercePharma: Novartis forges ahead with expansion at North Carolina vaccines campus, with $60M tech building. Report | Follow @FiercePharma

@EricPFierce: $65 million DSM cell culture plant in Brisbane part of Australia's $345 million Translational Research Institute. Story | Follow @EricPFierce

> Thanks to Lexapro generics, Forest swings to loss on 32% drop in yearly sales. More

> Biogen MS pill soars onstage with impressive first-week script numbers. Article

> Drugmakers, get ready for bigger, faster dealmaking, Moody's says. Story

Pharma Manufacturing News

> Novartis expanding U.S. vaccine complex. Item

> U.S. lawmakers take another shot at mandating drug tracking system. More

> Fujifilm expands former Merck biologics plant in U.K. News

> DSM sets June launch for Australian biologics plant. Article

Biotech Research News

 @EmilyMFierce: Intel, Oregon Health & Science University partner on genetic profiling project. More | Follow @EmilyMFierce

> Antibody genes linked to ethnicity. Item

> Autistic behavior has genetic basis in mice. Article

> Radioactive bacteria treatment stops metastasis in mice. More

> Columbia researchers identify hundreds of potential metabolic cancer targets. Story

Suggested Articles

It’s the final nail in the coffin for Catabasis’ Duchenne muscular dystrophy hopeful as edasalonexent has once again failed to deliver.

Journey Colab launches with $3 million from Apollo Projects to develop a pipeline of psychedelic compounds through a new development model.

Forma's lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with relapsed or refractory acute myeloid leukemia.